When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Nov 14
Have your own idea? Try our Stock Screener
U.S. Clinical Research and Equipment Industry Analysis
UpdatedNov 20, 2024
DataAggregated Company Financials
Companies66
- 7D-7.2%
- 3M-15.1%
- 1Y1.2%
- YTDn/a
Over the last 7 days, the Clinical Research and Equipment industry has dropped 7.2%, driven by a pullback from Thermo Fisher Scientific of 5.4%. In contrast, Quantum-Si has gained 76%. As for the longer term, the industry's performance has been flat for the past year. Looking forward, earnings are forecast to grow by 18% annually.
Industry Valuation and Performance
Has the U.S. Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 21 Nov 2024 | US$630.4b | US$142.4b | US$10.4b | 41.6x | 60.8x | 4.4x |
| Sat, 19 Oct 2024 | US$729.7b | US$141.8b | US$8.5b | 37.2x | 85.9x | 5.1x |
| Mon, 16 Sep 2024 | US$740.7b | US$141.8b | US$8.5b | 37.5x | 87.2x | 5.2x |
| Wed, 14 Aug 2024 | US$724.4b | US$141.5b | US$8.4b | 39x | 86.7x | 5.1x |
| Fri, 12 Jul 2024 | US$669.1b | US$141.3b | US$12.2b | 40.5x | 54.9x | 4.7x |
| Sun, 09 Jun 2024 | US$713.3b | US$141.3b | US$12.2b | 37.7x | 58.6x | 5x |
| Tue, 07 May 2024 | US$714.1b | US$141.7b | US$12.5b | 39.7x | 57.1x | 5x |
| Thu, 04 Apr 2024 | US$727.8b | US$142.1b | US$12.8b | 43.1x | 56.9x | 5.1x |
| Sat, 02 Mar 2024 | US$735.4b | US$142.2b | US$12.8b | 44.2x | 57.4x | 5.2x |
| Mon, 29 Jan 2024 | US$698.4b | US$153.8b | US$14.2b | 35.5x | 49.3x | 4.5x |
| Wed, 27 Dec 2023 | US$698.9b | US$153.8b | US$14.2b | 37.8x | 49.1x | 4.5x |
| Fri, 24 Nov 2023 | US$631.0b | US$153.8b | US$14.0b | 33.5x | 45x | 4.1x |
| Sun, 22 Oct 2023 | US$607.7b | US$154.6b | US$11.2b | 31.3x | 54.2x | 3.9x |
| Tue, 19 Sep 2023 | US$688.5b | US$154.6b | US$11.2b | 32.7x | 61.4x | 4.5x |
| Thu, 17 Aug 2023 | US$708.0b | US$154.6b | US$11.2b | 32.3x | 63.2x | 4.6x |
| Sat, 15 Jul 2023 | US$706.2b | US$155.5b | US$12.7b | 29.3x | 55.7x | 4.5x |
| Mon, 12 Jun 2023 | US$680.2b | US$152.4b | US$12.5b | 29.1x | 54.4x | 4.5x |
| Wed, 10 May 2023 | US$685.2b | US$152.2b | US$12.8b | 30.1x | 53.6x | 4.5x |
| Fri, 07 Apr 2023 | US$719.9b | US$154.6b | US$10.8b | 26.7x | 66.6x | 4.7x |
| Sun, 05 Mar 2023 | US$739.7b | US$154.5b | US$10.9b | 31x | 68x | 4.8x |
| Tue, 31 Jan 2023 | US$747.0b | US$155.5b | US$9.0b | 30.1x | 83.1x | 4.8x |
| Thu, 29 Dec 2022 | US$739.7b | US$155.2b | US$8.8b | 28.5x | 84.3x | 4.8x |
| Sat, 26 Nov 2022 | US$767.3b | US$155.1b | US$8.8b | 28.6x | 87.3x | 4.9x |
| Mon, 24 Oct 2022 | US$691.5b | US$152.9b | US$17.4b | 24.8x | 39.6x | 4.5x |
| Wed, 21 Sep 2022 | US$738.2b | US$152.3b | US$17.3b | 26.7x | 42.6x | 4.8x |
| Fri, 19 Aug 2022 | US$828.4b | US$152.3b | US$17.3b | 31.6x | 47.8x | 5.4x |
| Sun, 17 Jul 2022 | US$747.8b | US$148.1b | US$20.1b | 30.8x | 37.2x | 5.1x |
| Tue, 14 Jun 2022 | US$687.9b | US$148.1b | US$20.1b | 28.1x | 34.2x | 4.6x |
| Thu, 12 May 2022 | US$689.9b | US$147.7b | US$20.0b | 28.9x | 34.4x | 4.7x |
| Sat, 09 Apr 2022 | US$896.8b | US$146.5b | US$25.3b | 37.3x | 35.4x | 6.1x |
| Mon, 07 Mar 2022 | US$833.0b | US$146.2b | US$25.3b | 36.5x | 33x | 5.7x |
| Wed, 02 Feb 2022 | US$862.9b | US$139.4b | US$27.9b | 38.6x | 31x | 6.2x |
| Fri, 31 Dec 2021 | US$999.1b | US$138.0b | US$27.3b | 45.4x | 36.6x | 7.2x |
| Sun, 28 Nov 2021 | US$967.8b | US$138.0b | US$27.3b | 42.4x | 35.5x | 7x |
Price to Earnings Ratio
35.5x
Current Industry PE
- Investors are optimistic on the American Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 60.8x which is higher than its 3-year average PE of 56.2x.
- The 3-year average PS ratio of 5.0x is higher than the industry's current PS ratio of 4.4x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 28% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does U.S. Clinical Research and Equipment compare with similar industries?
| US Market | -1.19% | |
| Healthcare | -4.83% | |
| Life Sciences | -7.19% | |
| Clinical Research and Equipment | -7.19% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| QSI Quantum-Si | US$1.39 | 75.7% +US$85.4m | -8.6% | PS87.5x | |
| TKNO Alpha Teknova | US$7.74 | 23.8% +US$79.4m | 283.2% | PS11.4x | |
| BLFS BioLife Solutions | US$25.01 | 3.7% +US$41.7m | 84.3% | PS7.9x | |
| CDXC ChromaDex | US$7.50 | 7.0% +US$37.5m | 417.2% | PE386.6x | |
| SYNH Syneos Health | US$42.98 | 0.6% +US$24.9m | -8.8% | PE62.6x |